Esperion Therapeutics, Inc. Rings the Closing Bell

ABOUT THIS EVENT

Esperion Therapeutics, Inc. (Nasdaq: ESPR) visited the Nasdaq MarketSite in Times Square.

The experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.

In honor of the occasion, Tim Mayleben, President & CEO, rang the Closing Bell.